Navigation Links
Glythera Relocates to North East as Part of £2M Funding Round

NEWCASTLE, England, June 21, 2012 /PRNewswire/ --

Glythera, an emerging biopharmaceutical company specialising in protein/peptide functionalisation and glycosylation, has secured a fundraising round totalling £2M with IP Group, which will be tranched over the next three years.

The company, a spin-out from the University of Bath, has recently established commercial operations at Newcastle's INEX incubator facility, following an initial £600,000 investment split equally between IP Group and its managed fund, the Finance for Business North East Technology Fund. The next two tranches will be of a similar size and are contingent on certain milestones being met.

Glythera's relocation has led to the immediate creation of new research and development positions in the North East of England including the appointment of Dr David Simpson as Chief Operating Officer. David has over 15 years of experience in the biopharmaceutical industry, having held senior technical, managerial and leadership positions centred on the development and manufacturing of biopharmaceutical products destined for worldwide approval. Further growth is anticipated over the next three years in line with the company's commercial and technical needs.

Dr Anthony Baxter, Glythera's Chairman, commented: "We are obviously delighted to close this funding round in what remains a challenging environment. Our ability to do this is testament to the strength of the Glythera technology, combined with the leadership and technical skills of our team."

David added: "Relocating to the North East makes a lot of sense for us, due to the region's strong pedigree in biomanufacturing, giving us the ideal base from which to partner with leading companies and attract a skilled workforce."

Duncan Lowery, Senior Investment Manager at IP Group, commented: "As David has mentioned, the North East has a real strength in biomanufacturing and the fact that Glythera is relocating here demonstrates that the industry continues to develop and expand apace. The technology being developed is highly innovative and could transform the use of vaccines and therapeutics. With a revolutionary product and extremely experienced management team, we're confident that Glythera will hit its targets and continue to build a reputation as a rising star within the pharmaceutical industry."

For more information about Glythera, visit

For more information on the Finance for Business North East Technology Fund, visit:

About Glythera

Glythera Limited is a biotechnology company specialising in the development of enhanced protein/peptide therapeutics through the use of advanced glycosylation and conjugation technologies. Originally spun-out from the University of Bath, the Company relocated to the Newcastle-upon-Tyne INEX incubator facility in 2012, following investment from the IP Group and the Finance for Business North East Technology Fund. Gylthera's core technologies - Permalink and Permacarb - allow the selective and stable functionalisation and glycosylation of biopharmaceuticals for improved stability, bioavailability and efficacy.

About IP Group

IP Group is a leading UK intellectual property (IP) commercialisation company, developing technology innovations primarily from its research intensive partner universities. The Group offers more than traditional venture capital, providing its companies with access to business building expertise, networks, recruitment and business support.

The Company's portfolio comprises holdings in over 60 companies including Oxford Nanopore Technologies, the DNA sequencing development company, Revolymer, best known for its removable chewing gum and Xeros, which has received many accolades for its revolutionary clothes washing techniques with a much reduced requirement for water.

The portfolio includes early stage to mature businesses and has exposure to five main sectors - Energy & Renewables, Medical Equipment & Supplies, Pharma & Biotech, IT & Communications and Chemicals & Materials. To date, fourteen of the portfolio companies IP Group has backed have listed on the AIM market of the London Stock Exchange and one on PLUS Markets.

Founded in 2001, IP Group listed on AIM in October 2003 and moved to the Official List in June 2006. The Group now has long-term partnerships with twelve universities including those under its commercialisation agreement with Fusion IP plc.

For more information, please visit our website at

About The North East Technology Fund

The North East Technology Fund is a £25m venture capital fund dedicated to investing in technology businesses with outstanding potential which are based in, or are willing to relocate to, the North East of England. The Fund is managed by IP Group plc and is backed by the European Investment Bank and European Regional Development Funds. It is able to co-invest with other institutional, private or corporate investors and at all stages of the business cycle from early stage to mature businesses. Its investment range is from £50,000 to £1.25m.

For more information, please visit

About Finance for Business North East

Finance for Business North East is a £125m publicly-backed venture capital fund. It will support up to 850 small and medium-sized companies in North East England over the next five years, with the aim of creating more than 5,000 jobs.

The European Investment Bank is committing £62.5m into the fund with £44.25m coming from the European Regional Development Fund 2007-2013. North East Finance, based in Newcastle, manages the fund on a day-to-day basis.

Finance for Business North East is part of the Government's Solutions for Business portfolio of publicly funded help to companies to start, grow and succeed. Solutions for Business makes it easier for companies to get the advice and assistance that they need. More information on Solutions for Business can be found at

© 2012 kdm communications limited

SOURCE Glythera
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Northeastern University Nanomanufacturing Center Director Ahmed Busnaina to Present Webinar on “The Democratization of Manufacturing”
2. Instrumentation Laboratory Moves To Direct Distribution Of Hemostasis Product Line In North America
3. Northwest Bio and Fraunhofer IZI Announce Milestones Reached
4. OncoSec to Present at 10th Annual BioPartnering North America
5. Tengion Announces Relocation of Corporate Headquarters to Current Facility in Winston-Salem, North Carolina
6. Northwest Bio Reaffirms Its Freedom to Operate; Refutes Other Parties Misleading Patent Assertions
7. StemCyte Adds World Class Talent to its North America and Global Operations
8. Tengion Presents New Scientific Data in Presentations at TERMIS North America Annual Meeting
9. Northwest Bio Implements Major Balance Sheet Clean-Up
10. BioSpace Spotlights Northwests Life Science Community
11. U.S. Senate Urged to Increase Federal Funding for Research into Hereditary Angioedema, a Rare and Serious Genetic Disorder
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... device company specializing in imaging technologies, announced today that it ... as part of the Horizon 2020 European Union Framework Programme ... a large-scale clinical trial in breast cancer. , ... , --> --> The ...
(Date:11/25/2015)... 25, 2015 Studies reveal the ... plaque and pave the way for more effective treatment for ...     --> --> ... health problems in cats, yet relatively little was understood about ... studies have been conducted by researchers from the WALTHAM Centre ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... Organization of Black Aerospace Professionals (OPBAP) has been formalized with the signing of ... team leaders met with OPBAP leaders Capt. Karl Minter and Capt. Albert Glenn ...
(Date:11/24/2015)... Nov. 24, 2015  Asia-Pacific (APAC) holds the ... (CRO) market. The trend of outsourcing to low-cost ... but higher volume share for the region in ... however, margins in the CRO industry will improve. ... ( ), finds that the market ...
Breaking Biology Technology:
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has been ... provide preclinical development services to the National Cancer Institute ... will provide scientific expertise, modern testing and support facilities, ... preclinical pharmacology and toxicology studies to evaluate potential cancer ... The PREVENT Cancer Drug Development Program is an ...
(Date:10/29/2015)... health pioneer, Joseph C. Kvedar , MD, describes ... wellness, and the business opportunities that arise from it ... Healthy Things . Long before health and wellness ... vice president, Connected Health, Partners HealthCare, was creating a ... the hospital or doctor,s office into the day-to-day lives ...
(Date:10/27/2015)... Synaptics Inc. (NASDAQ: SYNA ), the leader ... adopted the Synaptics ® ClearPad ® Series ... newest flagship smartphones, the Nexus 5X by LG and ... --> --> Synaptics works closely with ... in the joint development of next generation technologies. Together, ...
Breaking Biology News(10 mins):